NCT00319930TerminatedPhase 1
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Pharmacodynamic Study of Intravenously Administered CNF1010 (17-(Allylamino)-17-demethoxy-geldanamycin [17-AAG]) in Patients With ZAP-70 Positive B-Cell Chronic Lymphocytic Leukemia (CLL)
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Terminated
- Sponsor
- Biogen
- Enrollment
- 10
- Locations
- 6
- Primary Endpoint
- Pharmacokinetics (PK)
Study Overview
Brief Summary
The purpose of the study is to evaluate the effects of increasing doses of CNF1010 on pharmacodynamic markers and hematological response.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Diagnosis of B-cell CLL including
- •Lymphocytosis of >=5,000 monoclonal B-cells/microliter co-expressing >= one B-cell marker (CD19, CD20, or CD23) and CD5 in peripheral blood AND
- •<= 55% prolymphocytes AND
- •Bone marrow with >=30% mononuclear cells being lymphocytes
- •ZAP-70 positive CLL
- •Intermediate or High risk, poor prognosis CLL refractory to fludarabine-based therapy as defined by one of the following:
- •Disease progression following 2 cycles of fludarabine OR
- •Failure to achieve PR or CR after at least 2 cycles OR
- •No response to treatment or stable disease after at least 2 cycles of fludarabine OR
- •Disease progression after chemotherapy treatment after fludarabine-based therapy
- •· CLL patients intolerant to fludarabine-based therapy. [Intolerance is defined as the development of any serious medical condition occurring after exposure to fludarabine that would restrict further use of the agent as treatment for the patient's CLL (i.e., autoimmune hemolytic anemia, myelosuppression, hypersensitivity)]
- •Indication for treatment as defined by the NCI Working Group Guidelines
- •Laboratory parameters as follows:
- •Hemoglobin >=10 g/dL (may be post-transfusion); platelet count >=50 x103/mm3
- •T. Bili <2 x ULN and ALT and AST <2 x ULN
- •Creatinine <=2 x ULN
- •ECOG Performance Score <=2
- •For patients of child-producing potential, use of effective contraceptive methods during the study and for 1 month following treatment
Exclusion Criteria
- •Pregnant or nursing women
- •Class III or IV cardiac disease defined by the New York Heart Association Functional Classification and/or left ventricular ejection fraction <40%
- •History of prior radiation that potentially included the heart in the field.
- •History of myocardial infarction or active ischemic heart disease within 6 months of study entry
- •History of arrhythmia (including atrial fibrillation, multifocal premature ventricular contractions, ventricular bigeminy or trigeminy, ventricular tachycardia or a requirement for antiarrhythmics (including digoxin)
- •Baseline QTc >=450 msec for men and >= 470 msec for women in the absence of correctable electrolyte imbalance
- •Poorly controlled angina
- •Congenital long QT syndrome or first-degree relative with unexplained sudden death <40 years of age
- •Presence of left bundle branch block
- •Treatment with chemotherapy, monoclonal antibody or radiotherapy within 28 days of study entry
- •Severe or debilitating pulmonary disease
- •Participation in any investigational drug study within 28 days prior to CNF1010 administration. (Patient must have recovered from all acute effects of previously administered investigational agents)
- •Presence of active malignancy with the exception of basal cell carcinoma
- •Active symptomatic fungal, bacterial and/or viral infection including active HIV or viral (A, B or C) hepatitis
- •Known allergy to soy
- •Requirement for concomitant therapy with drugs that alter metabolism by cytochrome P450 3A4 except low-dose warfarin for implanted device patency
- •Requirement for concomitant therapy with drugs that prolong or may prolong QTc interval
Outcomes
Primary Outcomes
Pharmacokinetics (PK)
Pharmacodynamics (PD)
The minimal biologically active dose (MBAD)
Safety and toxicity profile
Clinical and hematological response
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (6)
Loading locations...
Similar Trials
Completed
Phase 1
Phase 1 Study of TG01 and Erlotinib in Non-small Cell Lung Cancer (NCSLC) PatientsNon-small Cell Lung CancerNCT00569114Tragara Pharmaceuticals, Inc.45
Completed
Phase 1
A Study to Assess the Effects of Itraconazole and Rifampin on Lazertinib in Healthy Adult ParticipantsHealthyNCT04410094Janssen Research & Development, LLC32
Completed
Phase 1
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid TumorsNon Small Cell Lung CancerSquamous Cell Carcinoma of Head and NeckTriple Negative Breast CancerCastration Resistant Prostate CancerGastric/ Gastroesophageal JunctionPancreatic Ductal AdenocarcinomaColorectal CancerOvarian CancerHepatocellular CarcinomaBladder CancerSquamous Carcinoma of the Anal CanalNCT04580485Incyte Corporation54
Active, not recruiting
Phase 1
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid TumorsAdvanced Solid Tumors CancerNCT02988960AbbVie163
Completed
Phase 1
To Explore The Potential For PF-04531083 To Effect The Blood Concentrations Of Simvastatin And Its Main Acid Metabolite Following Co-Administration Of Both MedicationsChronic PainNCT01103739Pfizer24